The evolving treatment paradigm of multiple myeloma: From past to present and future

Turkish Journal of Hematology

Volumn 25, Issue 2, 2008, Pages 60-70

  Beksaç, Meral ^a   Delforge, Michel ^b   Richardson, Paul ^c  

^a ANKARA UNIVERSITY   (Turkey)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Multiple myeloma; Review; Treatment

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ACETYLSALICYLIC ACID; ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; METHOTREXATE; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN;

ANEMIA; ANOREXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; FATIGUE; GASTROINTESTINAL TOXICITY; HERPES ZOSTER; HUMAN; INFECTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MENTAL DISEASE; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; THROMBOGENESIS; TREATMENT OUTCOME;

EID: 48649088499     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Kyle R A, Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. Leukemia. 2005; 19:910-2.
2. Ösby E, Beksac M, Reizenstein P. Alternating combination chemotherapy does not delay development of refractoriness in myeloma. Anticancer Res. 1986; 6: 1145-7.
3. Kyle, RA Rajkumar S V (2004). Multiple Myeloma. NEJM 351: 1860-73.
4. Kumar A.,Loughran T.,Alsina M. Durie B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol. 2003; 4: 293-304.
5. Smith A., Wisloff F., Samson D.,on behalf of the UK Myeloma Forum, Nordic Myeloma Study Group and British Committee for Standards in haematology Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132: 410-51.
6. Durie BG, Harousseau JL. Miguel JS, Blade J, Bartogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boocadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-13.
7. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoletic stem cell transplantation. Br J Haematol 1998; 102: 1115-23.
8. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, lfrah N, Payen C, Bataille R. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7.
9. Child JA, Morgan GJ, Dervies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ; Medical Research Council Adult Leukaemia Working Party. High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma. N Engl J Med 2003; 348: 1875-83.
10. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbul A, Caravita T, Capaldi A; Pregrio P. Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus. C. Massaia M, Mandelli F, Carella AM, Poglani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052-7.
11. Barlogie B, Kyle RA, Anderson KC, Grepp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF Jr, Dakhil SR, Lanier KS, Chapman RA; Cromer JN, Salmon SE, Durie B, Crowley JC. Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-36.
12. Blade,J., Rosinol, L., Sureda A., et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the Initial chemotherapy: long-term results from a prospective. randomized trial fron the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-9.
13. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial. coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008; 24: 431-6.
14. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C; Cangini D, de Vivo A, Testoni N, Nicci C, Terragna.C, Grafone T, Perrone G, Ceccolini M, Tura S, Baccarani M; Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorublcindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005; 106: 35-9.
15. Macro M, Divine M, Uzunhan Y, Jaccard A, Bouscary D, Leblond V, Janvier M, Genet P, Castaigne S, Royer B, Allard C, Chevret S, Fermand JP. Dexamethasone+Thalidomlde (Dex/Thal) Compared to VAD as a Pre-Transplant Treatment In Newly Diagnosed Multiple Myeloma (MM): A Randomized Trial. Blood 2006;108:57a.
16. Cave M, Testoni N, Terragna C, Zamagni E, Taochetti P, Nicci C, Renzulli M, Montanari E, Perrone G, Cangini D, Grafone T, Cecoolini M, Brioli A M, Martinelli G, Tosi P, Baccaranl M. Up-Front Thalidomide-Daxamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14). Blood 2006;108:3081a.
17. Goldschmidt H, Sonneveld P, Breitkreuz I, van der Holt B, Benner A,. Barge R M.Y, Salwender H, Bos G M.J., Glasmacher A, Raymakers R, Scheid C, Huilgens PC., Naumann R, van Oers M H.J., Händ A, Vallenga E, Martin H, Wilermans P W., Ho A D., Westveer P H.M., Verhoef, G E.G. Mazitschek U, Lokhorst H M. HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years. Blood 2005:106:424a.
18. Richardson P, Anderson K. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol. 2006;24:334-6.
19. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishnai S, Fox M, Crowley J. Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. New Engl J Med 2006;354:1021-30.
20. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GM, Croockewit S, Zweegman S, Breitkreuz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MH, Schaafsma, R, Naumann R, Sinnige H, Blau I, Verhoef G, de Weerdt O, Wijermans P, Wittebol S, Duersen U,Vellenga E, Goldschmidt H; Dutch-Belgian HOVON; German GMMG. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica. 2008;93:124-7.
21. Harousseau J L, Merit G,Caillot D, Casassus P, Facon T, Mohty M, Maloisel F, Malsonneuve H, Chaleteix C, Benboubker L, Esseltine D L, Attal M. VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MR: An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial. Blood 2006,108:56a.
22. Richardson P. G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S. V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R. Z., Kuter D., Limentani S. A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D. P., Anderson K. C. A Phase 2 Study of Bortezomlb in Relapsed, Refractory Myeloma. N Engl J Med 2003;348:2609-17.
23. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol. 2004;22:1857-63.
24. Kyle R., Leong T., Li S., et al. Complete response in multiple myeloma clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006,106:1958-66.
25. Dlspenzieri A.,Blood E.,Vesole D. Etal. A phase II study of PS-341 for patients with high risk newly diagnosed multiple myeloma: a trial of the Eastern Coopertaive Group (E2AO2). Blood 2005;106:2546a Badogle B, Tricot G. Complete response in myeloma: a Trojan horse? Blood 2006:108: 2134.
26. Jagannath S, Dude BG, Wolf J, Camacho E, Irwin D, Lutzky J, McKinley M, Gabayan E, Mazumder A, Schenkein D, Crowley J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple, myeloma. Br J Haematol. 2005;129:776-83.
27. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H. Bortezomib plus dexamethasone as Induction treatment prior to autologous stem cell transplantation In patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006;91:1498-505.
28. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously, untreated patients with multiple myeloma. Br J Haematol. 2005:129:755-62.
29. San-Miguel J, Bladé J. Perspective on the current use of bortezomib in multiple myeloma.Haematologica 2006;91:871.
30. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE,Gertz MA.Combination therapy with lenalldomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.Blood. 2005;106:4050-3.
31. Cavo M, Baccarani M, The Changing Landscape of Myeloma Therapy. New Engl J Med 2006:354(10): 1076-1078.
32. Facon T, Mary JV, Pégourie B. et al. Dexamethasone-based regimens versus melphalan-prednisone for eldery multiple myeloma patients ineligible for high-dose therapy. Blood 2006,107:1292-8.
33. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Canglalosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M; Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
34. Facon T, Mary J.Y., Hulin C., Benboubker L., Attal M., Renaud M., Harousseau J.L., Pegourie B., Guillerm G. Chaleteix C., Dib M., Voillat L., Malsonneuve H., Troncy J., Dorvaux V., Moncondult M., Martin C., Casassua P., Jabert J., Jardell H., Kolb B Bauters F., Melphalan and prednisone plas thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stan cell transplantation in elderly patients with Multiple Myeloma (IFM 99-06): a randomised trial. Lancet 2007;370: 1209-18.
35. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Medavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegri A, Oriol A, Carrara D, Garía-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study Blood, 2006;108:2165-72.
36. Offidani M, Corvatta L, Plersantelli MN, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Ferrenti M, Rupoli S, Scortechinl AR, Gluliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Poloni A, Polloni C, Marconi M, Leoni P. Thalidomide, dexamethasone, and pegylated liposomal doxorubacin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood, 2006;108: 2159-64.
37. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badrons A, Zangari M, Anaissie E, Eostein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patient Blood. 2001;98:492-4
38. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999 18;341:1565-71.
39. Jagannath S, Richardson PG, Sonneveid P, Schuster MW, Irwin D, Stadtmauer EA, Faconn T, Harousseau JL, Cowan JM, Anderson KC. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-7.
40. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D.Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/ refractory multiple myeloma.Leuk Res. 2007;31:779-82.
41. Palumbo A, Falco P, Falcone A, Corradini P, Di Raimonde F, Giullani N, Rossi G, Morabito F, Canepa L, Gozzetti A, Ambrosimi M T, Zeldis J, Knight R, Foa R, Boccadoro M, Petrucci M T. Oral Revimid® Plus Melphalan and Prednisone (R-MP.) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phasme I/II Study. Blood 2006,108:800a.
42. Sonnevld P, Suclu S, Weljermaris P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B; European Organization for Research and Treatment of Cancer (EORTG); Leukemia Cooperative Grpup (LCG); Dutch Haemato-Oncology Coorperative Study Group (HOVON). Cyclosporin A combined with vincristine, doxorubicin, and dexamethasonene (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma an EORTC-HOVON randomized phase III study (06914).Br J Haematol. 200T;115:895-902.
43. Hari P, Pasquini MC, Vesola DH. Cure of multiple myeloma - more hype, less reality. Bone Marrow Transplant. 2006;37:1-18.
44. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschluter M. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006;132:584-93.
45. Dimopoulos, M A, Spencer A. Attal M., Prince M, Harousseau JL,, Dmoszynska A, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). 2005 106(11): Abstract 6a.
46. Richardson PG, Blood E. Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyl M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108:3458-64.
47. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;1; 61:3071-6.
48. Richardson P. G., Sonneveld P., Schuster M. W., Irwin D., Stadtmauer E. A, Faoon T., Harousseau J.-L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San-Miguel J. F., Bladé J., Boccadoro M., Cavanagh J., Dalton W. S., Boral A. L., Esseltine D. L. Porter J. B.. Schenkein D., Anderson K. C., the Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high dose dexamethasone for relapsed myeloma. N Engl J Med 2005;352:2487-98.
49. Wang M, Delasalle K, Giralt S, Alexanian R, Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy. Blood 2005;106:784a.
50. Chanan-khan A A, Padmanabhan S, Miller K C, Musiel L, Yu J, Bernstein Z P, Manochakian R, Czuczman M S, Final Results of a Phase II Study of Bortezomib (Velcade) in Combination with Liposomal Doxorubicin (Doxil) and Thalidomide (VDT) Demonstrate a Sustained High Response Rates in Patents (pts) with Relapsed (ref) or Refactory (ref) Multiple Myeloma. Blood 2006,1108:3539a.
51. Harousseau J L, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, Robak T, Xiu L, Zhuang S H, Orlowski R Z. Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone.J Clin Oncol 2007,25: 8002.
52. Heider U, Kaiser M, Müller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol. 2006;77:233-8.
53. Zangari M, Esseltine D, Lee CK, Badogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P. Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005;131:71-3.
54. Laura R, Cibeira MT, Uriburu C, Yantomo S, Salamero O, Bladé J, Montserrat E. Bortezomib: an effectIve agent in extramedullary disease in multiple myeloma. Eur J Haematol. 2006;76:405-8.
55. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000;11:1427-36.
56. Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P, Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.. Haematologica. 2006;91:1722-3.
57. Brinker BT, Waller EK, Leong T et al. Maintenance therapy with. thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006;106:2171-80.
58. Attal M, Harousseau JL, Leyvraz S, Doyen C, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006;108:3289-94
59. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ. The role of second autografts in the managemeht of myeloma at first relapse.Haematologica. 2006;91:141-2.
60. Bariogle B., Analssie E., Haessler J., van Rhee F., Pineda-Roman M., Hollmig K., Alsayed Y., Epstein J., Shaughnessy J. D., Cowleg J. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in Multiple Myeloma. Cancer. 2008: a head of publication.